A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Stopped Study stopped at interim analysis point, due to lack of study subjects to recruit.

Conditions

• Severe to Critical COVID 19 With Associated ARDS

Interventions

• DRUG: FP-025 100 mg
• DRUG: FP-025 300 mg
• DRUG: Placebo

Sponsor

Foresee Pharmaceuticals Co., Ltd.